Eight systematic reviews with network meta-analysis were identified that compared newer biologics with older biologics in patients with moderate-to-severe plaque psoriasis. There was extensive overlap of primary studies across the systematic reviews and network meta-analyses. Newer biologics such as secukinumab, ixekizumab, brodalumab and risankizumab were more favourable compared to older biologics (adalimumab, etanercept, and ustekinumab) in reaching 90% or 100% skin clearance, as measured

more »

... h the Psoriasis Area Severity Index. The risk of side effects was similar between the newer and older biologics.